Emris Pharma
Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients
Company Overview
Snapshot
Founded in May 2023 by Lyora Aharonov, Emris Pharma operates with 1–10 employees. The company secured its Pre-Seed funding round in May 2023, with NGT HealthCare II participating as a lead investor. This funding supported the launch of its innovative topical drug development.
Business overview
Emris Pharma is a Health Tech and Life Sciences company focused on developing novel small molecule, topically administered drugs to prevent skin toxicities induced by EGFR inhibitors (EGFRi). Its core product, SDT 011 (EMR-001), aims to improve the quality of life and treatment compliance for cancer patients by blocking the initial trigger of skin toxicity. The company targets a global market with unmet needs, anticipating growth due to new cancer treatment combinations involving EGFRi and emerging bi-specific antibodies.
Strategic signal
In June 2023, Emris Pharma, a spin-off of Hadasit and Yissum, officially launched the development of its innovative topical drug. This launch signals the company's entry into the pharmaceutical market with a focus on improving cancer patient care, indicating a strategic move towards addressing a significant unmet medical need and enhancing treatment adherence.
Log in to access full profile ›Company Intelligence Q&A
- When was Emris Pharma founded?
- Emris Pharma was founded in May 2023.
- Who are the founders of Emris Pharma?
- Lyora Aharonov is a co-founder and CEO of Emris Pharma.
- What is Emris Pharma's primary focus?
- Emris Pharma focuses on developing a novel small molecule, topically administered drug to prevent skin toxicities induced by EGFR inhibitors, aiming to improve cancer patients' quality of life and compliance with therapy.
- Which investors participated in Emris Pharma's Pre-Seed funding round?
- In May 2023, Emris Pharma received Pre-Seed funding from NGT HealthCare II and the Israel Innovation Authority.
- What is the significance of Emris Pharma's launch?
- Emris Pharma launched in June 2023 as a spin-off of Hadasit and Yissum, initiating the development of a new topical drug designed to treat skin toxicities and improve the quality of life for cancer patients.